Amcenestrant

Amcenestrant is a novel oral selective estrogen receptor degrader (SERD) that is being evaluated for the treatment of estrogen receptor-positive (ER+) breast cancer.^[1]

Amcenestrant

Identifiers
IUPAC name 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
CAS Number	2114339-57-8
PubChem CID	130232326
DrugBank	DB17864
ChemSpider	76117729
UNII	TBF1NHY02O
KEGG	D12145
ChEMBL	ChEMBL4475463
Chemical and physical data
Formula	C31H30Cl2FNO3
Molar mass	554.48 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC2=C(C=CC(=C2)C(=O)O)C(=C(C1)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)O[C@H]5CCN(C5)CCCF
InChI InChI=InChI=1S/C31H30Cl2FNO3/c32-23-8-12-27(29(33)18-23)28-4-1-3-21-17-22(31(36)37)7-11-26(21)30(28)20-5-9-24(10-6-20)38-25-13-16-35(19-25)15-2-14-34/h5-12,17-18,25H,1-4,13-16,19H2,(H,36,37)/t25-/m0/s1 Key:KISZAGQTIXIVAR-VWLOTQADSA-N

Phase III trial for breast cancer in Japan had started, but this trial has been discontinued.^[2]